Von Willebrand Disease News and Research

Latest Von Willebrand Disease News and Research

Thought leaders gather to examine challenges facing patients with primary immunodeficiencies

Thought leaders gather to examine challenges facing patients with primary immunodeficiencies

CSL Behring presents Hizentra study data against PI at AAAAI meeting

CSL Behring presents Hizentra study data against PI at AAAAI meeting

Grifols receives FDA approval for Alphanate to treat vCJD

Grifols receives FDA approval for Alphanate to treat vCJD

FDA approves sBLA for CSL's Hizentra to treat PI

FDA approves sBLA for CSL's Hizentra to treat PI

FDA grants CSL Behring marketing approval for Corifact in treatment of congenital FXIII deficiency

FDA grants CSL Behring marketing approval for Corifact in treatment of congenital FXIII deficiency

Rare bleeding disorder misdiagnosed

Rare bleeding disorder misdiagnosed

CSL Behring receives marketing approval for HAE drug Berinert in Israel

CSL Behring receives marketing approval for HAE drug Berinert in Israel

Baxter fourth quarter net income declines 26% to $423 million

Baxter fourth quarter net income declines 26% to $423 million

Octapharma supports development of 'Diagnosis and Management of von Willebrand Disease' CE supplement

Octapharma supports development of 'Diagnosis and Management of von Willebrand Disease' CE supplement

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

Clinical Immunology Research Laboratory at The Mount Sinai Medical Center receives Octapharma grant

LFB receives positive review feedback for closing of Willfact 1000 IU Mutual Recognition Procedure

LFB receives positive review feedback for closing of Willfact 1000 IU Mutual Recognition Procedure

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

New objective criteria for evaluating hemostatic efficacy in treatment of VWD

rVWF safe in patients with type 3 and severe type 1 von Willebrand disease, suggests interim study data

rVWF safe in patients with type 3 and severe type 1 von Willebrand disease, suggests interim study data

CSL Behring launches next generation HeliTrax System for Apple's devices

CSL Behring launches next generation HeliTrax System for Apple's devices

Researchers investigate Human-cl rhFVIII factor for severe hemophilia A treatment

Researchers investigate Human-cl rhFVIII factor for severe hemophilia A treatment

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

CSL Behring creates Interlaken Leadership Awards to support innovative immunoglobulin research

Octapharma USA accepts applications for 25th Anniversary Grants Program

Octapharma USA accepts applications for 25th Anniversary Grants Program

Vivaglobin therapy effective for patients with primary immunodeficiency

Vivaglobin therapy effective for patients with primary immunodeficiency

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Privigen IVIg therapy effective for primary, secondary immunodeficiencies: Study

Hizentra therapy effective for primary immunodeficiency patients

Hizentra therapy effective for primary immunodeficiency patients